In this paper, we address the question of 'Why do firms publish scientific papers?'. Research
examining the competitive advantages that firms accrue from investment in R&D has …

This paper identifies the degree to which scientists are willing to change the direction of their
work in exchange for resources. Data from the National Institutes of Health are used to …

New ideas no longer fuel economic growth the way they once did. A popular explanation for
stagnation is that good ideas are harder to find, rendering slowdown inevitable. We present …

The NIH (National Institutes of Health) is the largest single funder of biomedical research in
the world. This paper documents tensions between the agency's health and science …

Patient organisations play an increasingly crucial role in the pharmaceutical sector, yet their
impact on innovation remains unexplored. We estimate the impact of patient organisations …

Private interest groups lobby politicians to influence public policy. However, little is known
about how lobbying influences the policy decisions made by federal agencies. We study this …

Media industries typically exhibit two fundamental features, high fixed costs and
heterogeneity of consumer preferences. Daily newspaper markets, for example, tend to …

The mix of public and private research funding investments in alternative energy presents a
challenge for isolating the effect of government R&D funding. Factors such as energy prices …

Prior literature has established a link between changes in market size and pharmaceutical
innovation; whether a link exists with scientific research remains an open question. If …

We examine trends in the productivity of the pharmaceutical sector over the past three
decades. Motivated by Ricardo's insight that productivity and rents are endogenous to …